Predictors of hematoma expansion in intracerebral hemorrhage associated with factor Xa inhibitors [PDF]
Frontiers in NeurologyBackgroundImproving the outcomes of patients with intracerebral hemorrhage (ICH) associated with factor Xa inhibitors remains a clinical challenge. Andexanet alfa, a specific reversal agent for factor Xa inhibitors, has the potential to mitigate hematoma
Yoji Komatsu +9 more
doaj +2 more sources
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors [PDF]
Clinical Pharmacology: Advances and Applications, 2015 Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj +1 more source
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]
Scientific ReportsDirect oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano +8 more
doaj +2 more sources
The role of factor Xa inhibitors in venous thromboembolism treatment [PDF]
Vascular Health and Risk Management, 2015 Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Cabral KP, Ansell JE
doaj +2 more sources
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? [PDF]
Advances in Hematology, 2011 The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative.
Ali Zalpour +4 more
doaj +2 more sources
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Journal of Blood Medicine, 2017 Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S +5 more
doaj +1 more source
Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis [PDF]
Clinical and Applied Thrombosis/HemostasisBackground Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease (ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of cardiovascular diseases.
Meimei Xiong MS +2 more
doaj +2 more sources
Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review
Thrombosis UpdateHeparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality.
Colton Jones +7 more
doaj +2 more sources
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors [PDF]
TH OpenBackground Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Mark Goldin +16 more
doaj +2 more sources
AN IN-SILICO STUDY OF SOME NATURAL AND SYNTHETIC COMPOUNDS AS POTENTIAL INHIBITORS FOR FACTOR XA [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2022 Recent research has demonstrated the significance of factor Xa and its inhibitors as a possible treatment approach. Since currently approved drugs have a wide variety of side effects, new anticoagulants must be developed.
Lara AlBeik +2 more
doaj +1 more source